Mycobacterium tuberculosis

From IDWiki
Mycobacterium tuberculosis /
Revision as of 04:02, 14 November 2019 by Aidan (talk | contribs) (: added second line agents)
  • Mycobacterium tuberculosis causes tuberculosis
  • Most commonly pulmonary TB but extrapulmonary tuberculosis is possible (including adenitis, gastrointestinal TB, pericarditis, meningitis)
  • Standard treatment for susceptible TB is RIPE x2mo then RI x4mo

Background

Microbiology

  • Fastidious, aerobic acid-fast bacillus
  • Cell wall has high lipid content
  • Generation time is very long (15 to 20 hours)
  • M. tuberculosis is a complex that comprises seven species:
    • M. tuberculosis sensu stricto: most common causative organism worldwide
    • M. africanum: 50% of cases in West africa
    • M. canetti: rare cause in Eastern African
    • M. bovis: disease in cattle but can infect humans
    • M. caprae: disease in cattle
    • M. microti: disease in rodents
    • M. pinnipdeii: disease in seals, with rare human infection

Epidemiology

  • Typically spread via airborne route
    • Droplets are expelled during coughing, sneezing, or talking, and are suspended in the air
    • They can remain for up to 30 minutes
    • Killed by ultraviolet light
    • Not transmitted via fomites
  • About a third of the world is infected, mostly as latent tuberculosis
    • This progresses to active tuberculosis at about 3 or 4% in the first year and 5% over the rest of their life
  • Reinfection accounts for ~40% of active tuberculosis in endemic countries
  • Highest rates in sub-Saharan Africa and south/southeast Asia

Risk Factors

  • Source factors, such as sputum smear positivity, cough, cavitations
  • Exposure duration, closeness of contact
  • Factors in the exposed person, such as immune compromise, HIV status

Clinical Presentation

Classification

  • Primary vs. reactivation vs. reinfection
  • Latent vs. active

Primary tuberculosis

  • Primary tuberculosis is usually asymptomatic
  • Possible presentations include mild URTI with cough and/or fever
  • May be seen on CXR as infiltrate in mid-lung zones with hilar adenopathy
  • Ghon complex, especially in children
  • May progress in children and the immunocompromised patients
  • Immunological phenomena
    • Erythema nodosum
    • Phlyctenular conjunctivitis
    • Erythema induratum

Pulmonary tuberculosis

Extra-pulmonary tuberculosis

Latent tuberculosis

Investigations

  • Radiography: chest x-ray with or without CT chest
    • Primary TB: consolidation, lymphadenopathy, pleural effusion, Ghon complex
    • Reactivation TB: patchy upper-lobe consolidation, cavitation, fibrosis, pleural disease
    • Miliary TB: uniform 1-3 mm diameter diffuse nodules
  • Microbiology:
    • Samples can include routine or induced sputum (x3) or bronchoscopy, or tissue sample
    • Spontaneous sputum should include at least one morning sputum, ideally, but can be done all in a row at least one hour apart if needed
    • Acid-fast bacillus culture of sputum x3 is about 70% sensitive, and PCR (ANTB) x1 is about 75% sensitive

Management

Immune reconstitution inflammatory syndrome (IRIS)

Drug-induced liver injury (DILI)

  • Most common complication leading to treatment interruption, with a mortality of 6-12% if drugs are not stopped
  • Pyrazinamide, followed by isoniazid, then rifampin, are the most common causes of liver injury12
  • Most patients can have the same TB drugs reintroduced without recurrence of DILI, though recurrence can be delayed
  • Procedure
    • Hold if ALT >120 and symptoms, if ALT >200 even without symptoms, or bili >2x ULN
    • Switch to second-line meds
    • Reintroduce the original drugs once AST & ALT are <2x ULN
    • Only rechallenge with pyrazinamide if it was a mild case

Adherence to Treatment

Further Reading

References

  1. ^  Daphne Yee, Chantal Valiquette, Marthe Pelletier, Isabelle Parisien, Isabelle Rocher, Dick Menzies. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2003;167(11):1472-1477. doi:10.1164/rccm.200206-626oc.
  2. ^  Jussi J. Saukkonen, David L. Cohn, Robert M. Jasmer, Steven Schenker, John A. Jereb, Charles M. Nolan, Charles A. Peloquin, Fred M. Gordin, David Nunes, Dorothy B. Strader, John Bernardo, Raman Venkataramanan, Timothy R. Sterling. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. American Journal of Respiratory and Critical Care Medicine. 2006;174(8):935-952. doi:10.1164/rccm.200510-1666st.